'Living Drug' That Fights Cancer by Harnessing Immune System Clears Key Hurdle
NYTimes also covers the story (<a href="https:&#x2F;&#x2F;www.nytimes.com&#x2F;2017&#x2F;07&#x2F;12&#x2F;health&#x2F;fda-novartis-leukemia-gene-medicine.html" rel="nofollow">https:&#x2F;&#x2F;www.nytimes.com&#x2F;2017&#x2F;07&#x2F;12&#x2F;health&#x2F;fda-novartis-leuke...</a>) with more discussion about individual patients.<p>From the NYT article:<p>&gt; The panel recommended approving the treatment for B-cell acute lymphoblastic leukemia that has resisted treatment, or relapsed, in children and young adults aged 3 to 25.<p>Why so young?